Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023

22.05.2023 - Investigational New Drug (IND) application and Clinical Trial Application (CTA) for IMVT-1402 cleared by the FDA and MEDSAFE, respectivelyPhase 1 clinical trial in healthy subjects initiated in New ZealandPhase 2 proof-of-concept clinical trial of ...

Related Keywords

Germany , New Zealand , Chau Cheng , Clinical Development Updates , Exchange Commission , Immunovant Inc , Due To Roivant Sciences Ltd , Drug Administration , Fiscal Fourth Quarter Ended March , Fiscal Year Ended March , Private Securities Litigation Reform Act , Annual Report , Roivant Sciences , Immunovant ,